Gara Jalqabaatti › Lymphoma › Texas › Houston
Qorannoo klinikaalii Lymphoma Houston, TX keessatti
Qorannoo 34 Lymphoma f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Namoota walitti qabaa jiraSadarkaa 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Namoota walitti qabaa jiraQorannoo ilaalaa
- Texas Children's Hospital, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas M D Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Namoota walitti qabaa jiraSadarkaa 1/2
- Dren Investigational Site, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Namoota walitti qabaa jira
- MD Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Namoota walitti qabaa jiraQorannoo ilaalaa
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Namoota walitti qabaa jiraSadarkaa 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Qorannoo Lymphoma magaalota biroo keessatti
- Boston, MAQorannoo 33
- New York City, NYQorannoo 33
- Washington, DCQorannoo 23
- Baldwin Park, CAQorannoo 21
- Chicago, ILQorannoo 20
- Durham, NCQorannoo 17
- St. Louis, MOQorannoo 15
- Philadelphia, PAQorannoo 15
- Cleveland, OHQorannoo 14
- Edison, NJQorannoo 12
- Atlanta, GAQorannoo 12
- Seattle, WAQorannoo 12
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.